Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Laura Cicconi, Jad Othman, Alessandra Spagnoli, Enrico Attardi, Eleonora De Bellis, Pilar Lloret Madrid, Tamara Castaño, Juan Miguel Bergua Burgues, Arianna Savi, Ida Carmosino, Roberta Mazzarella, Armando Mena Duran, Mar Tormo, Susana Vives, Emília Cortesão, Fernanda Trigo, Mercedes Colorado, Lorenzo Algarra, Olga Salamero, José Antonio Pérez-Simón, Esther Perez, ANA Yurena Oliva Hernandez, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Claudia Lucia Scossa Melo, Cristina Gil, Marta Valero Núñez, Luis Felipe Casado Montero, Teresa Olave, Maria Vidriales Vicente, Carla Amigo, Irene Navarro Vicente, Cristian Escolano Escobar, Pilar Herrera Puente, Kenny Galvez, Rosalia Riaza Grau, Annalina Piccioni, Davide Facchinelli, Enrico Santinelli, Raffaele Palmieri, Giovanni Luzi, Monica Piedimonte, Sabrina Mariani, Luana Fianchi, Carmela Gurrieri, Ilaria Tanasi, Davide Lanzarotto, Fabio Guolo, Salvatore Perrone, Elisabetta Todisco, Anjum Khan, Victoria Campbell, Maria Teresa Voso, Daniela Cilloni, Adriano Venditti, Roberto Latagliata, Richard Dillon, Massimo Breccia, Luca Maurillo, Susanna Fenu, Alessandro Pulsoni, Pau Montesinos

Blood (2025) 146 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2025-3437

Published: 2025

Journal Articles

Preliminary results from RIVER-81, a phase 2 study of romaciclib (RVU120) + venetoclax in patients with acute myeloid leukemia failing first-line venetoclax + hypomethylating agent (HMA)

Blood (2025) 146 (Supplement 1): 3424.

https://doi.org/10.1182/blood-2025-3424

Published: 2025

Journal Articles

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Jorge Labrador, David Martinez-Cuadron, Cristina Gil, Mar Tormo, Josefina Serrano, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Jose-Mario Mariz, Fernanda Trigo, Teresa Bernal Del Castillo, Juan Miguel Bergua Burgues, Carlos Rodríguez-Medina, Olga Salamero, Joana Brioso Infante, Juan Manuel Alonso-Dominguez, Pilar Herrera Puente, María Luz Amigo, Susana Vives, Raimundo García-Boyero, Lorenzo Algarra, Mercedes Colorado, Monica Romero, Claudia Sossa, Maria Vidriales Vicente, Armando Mena Duran, Celina Benavente, Esperanza Lavilla-Rubira, Maria Jose Sayas Lloris, Emília Cortesão, Veronica Lizama, Olga Arce-Fernández, María García-Fortes, Maria Dolores Madrigal, Manuel Perez Encinas, Marta Valero-Nuñez, Luis Felipe Casado Montero, Maria Teresa Olave Rubio, Ágata Almela, Diana Cuervo, Victor Noriega Concepción, Marcela Espinoza, Beatriz De Rueda Ciller, Manuel Barrios García, Rosa Fernández, Bernardo González González, Carmen Montes, Christine Rojas, Esther Pérez-Santaolalla, María Lourdes Amador Barciela, ANA Yurena Oliva Hernandez, Rebeca Rodriguez-Veiga, Isabel Cano, Evelyn Acuña-Cruz, Antonio Solana-Altabella, Pau Montesinos

Blood (2025) 146 (Supplement 1): 875.

https://doi.org/10.1182/blood-2025-875

Published: 2025

Journal Articles

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Thomas Cluzeau, Pierre Yves Dumas, Pau Montesinos, Gaia Ciolli, Céline Berthon, Felicetto Ferrara, Adriano Venditti, José Antonio Pérez-Simón, Maria Calbacho, Richard Noppeney, Monia Lunghi, Chiara Cattaneo, Fabrizio Pane, Francesco Lanza, Juan Miguel Bergua Burgues, Alessandro Isidori, Yngvar Floisand, Vinay Jain, Eunice Wang

Blood (2025) 146 (Supplement 1): 767.

https://doi.org/10.1182/blood-2025-767

Published: 2025

Journal Articles

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Blood (2025) 146 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2025-1719

Published: 2025

Journal Articles

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Blood (2025) 146 (Supplement 1): 63.

https://doi.org/10.1182/blood-2025-63

Published: 2025

Journal Articles

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Rafael Colmenares, Eva Barragán, Rebeca Rodriguez-Veiga, Laura Torres-Miñana, Joaquín Sánchez-García, Mar Tormo, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Cristina Gil, Elena Soria-Saldise, Josefina Serrano, Mercedes Colorado, María García-Fortes, Cristina Bilbao, José Luis López Lorenzo, Maria Jose Larrayoz, Esther Pérez-Santaolalla, Esperanza Lavilla-Rubira, Lorenzo Algarra, Maria Carmen García-Garay, Carmen Chillon, Melissa Torres-Ochando, Raimundo García-Boyero, Carmen Couto, Ágata Almela, Victor Noriega Concepción, Marta Callejas, Manuel Barrios García, Soledad Casado, Amaia Balerdi Malcorra, Ana Cabello, Jorge Labrador, María Carmen Mateos, María Luz Amigo, Manuel Pérez-Encinas, Maria Jose Garcia, Lisette Costilla-Barriga, Juan Miguel Bergua Burgues, Gonzalo Carreño, Joaquin Martinez-Lopez, Rosa Ayala Diaz, Pau Montesinos

Blood (2025) 146 (Supplement 1): 6998.

https://doi.org/10.1182/blood-2025-6998

Published: 2025

Journal Articles

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3704.

https://doi.org/10.1182/blood-2025-3704

Published: 2025

Journal Articles

Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study

Beatriz Martín Herreros, Irene Navarro Vicente, Milena Sitkiewicz, Pilar Lloret Madrid, Łukasz Targoński, Amparo Sempere, Joaquín Sánchez-García, Josefina Serrano, Manuel Perez Encinas, Jorge Labrador, Delfim Duarte, Tomás Rivero Equiza, Olga Salamero, Rafael Colmenares, Maria Teresa Cedena Romero, Tamara Castaño, Anna Armatys, Alberto Giménez Conca, Cristina Gil, Teresa Olave, Lorenzo Algarra, María García-Fortes, Juan Miguel Bergua Burgues, Gabriela Rodriguez Macias, Manuel Barrios García, Eduardo Rodríguez-Arbolí, Teresa Caballero-Velazquez, Dunia De Miguel, Fernanda Trigo, Joana Brioso Infante, Emilia Ulenberg, Bruno Paiva, Virginia Pradillo Fernandez, Mar Tormo, Victor Noriega Concepción, Teresa Bernal Del Castillo, Rolando Omar Vallansot, Mercedes Colorado, Lisette Costilla-Barriga, Matxalen Olivares Salaverri, Isabel Simón-Pilo, Nerea Caminos, Ada Esteban-Figuerola, Małgorzata Sobczyk-Kruszelnicka, Renata Guzicka-Kazimierczak, Krzysztof Lewandowski, Andrzej Szczepaniak, Santiago Cranco, Manuela Clavijo, Irene Rey, Magdalena Karasek, Antonio Solana-Altabella, Leticia Rapan, Marta Sobas, Pau Montesinos

Blood (2025) 146 (Supplement 1): 218.

https://doi.org/10.1182/blood-2025-218

Published: 2025

Journal Articles

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

Anna Torrent, Mireia Morgades, Susana Barrera, Jordi Ribera, Eulàlia Genescà, José González-Campos, Nuria Martinez-Cibrian, Pau Montesinos, Alberto Hernández-Sánchez, Pere Barba, Edgar Zapico, Ricardo Sanchez, Marta Sitges Arriaga, Clara Maluquer Artigal, Esperanza Such, Carmen Botella, Maria Queipo De Llano, Mónica Cabrero Calvo, Ana Maria Vicent Castelló, Paula Lopez de Ugarriza, Mar Tormo, Bernardo Gonzalez Gonzalez, Irene García-Cadenas, Carlos Rodriguez Medina, Pilar Martínez-Sánchez, Arancha Bermúdez, Ignacio Gómez-Centurión, María Herrero García, Juana Ciudad, María Hermosín-Ramos, Josefina Serrano, Jose Angel Raposo Puglia, Laura Solán Blanco, Verónica Roldán Galiacho, María Almudena De Laiglesia Lorenzo, Lucía Gómez Pérez, María Solé Rodriguez, Mará Sol Casado Calderón, Laura Llorente González, Daniel Barrios Decoud, Ferran Vall-Llovera Calmet, Lorenzo Algarra, María Lourdes Amador Barciela, Raimundo Garcia, Antonia Cladera Serra, Juan Miguel Bergua Burgues, Isabel Granada, Jesus Maria Hernandez Rivas, Alberto Orfao, Josep-Maria Ribera

Blood (2025) 146 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2025-1564

Published: 2025

Journal Articles

Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

Blood (2025) 146 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2025-4988

Published: 2025

Journal Articles

Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study

Gaspar Aspas Requena, Rebeca Rodriguez-Veiga, Cristina Gil, Carmen Botella, Eliana Aguiar, Fernanda Trigo, Mercedes Colorado, Teresa Bernal Del Castillo, Eva Barragán, Mar Tormo, Eduardo Rodríguez-Arbolí, Josefina Serrano, Raimundo García-Boyero, Tamara Castaño, Pilar Herrera Puente, Monica Romero, Maria Jose Sayas Lloris, Lorenzo Algarra, Carlos Rodríguez-Medina, Claudia Sossa, Jorge Labrador, Susana Vives, María Luz Amigo, Olga Salamero, Marta Valero Núñez, Christine Rojas, Veronica Lizama, María García-Fortes, María-Belén Vidriales, Celina Benavente, Maria Dolores Madrigal, Marcela Espinoza, Manuel Pérez-Encinas, María Lourdes Amador Barciela, Guiomar Bautista Carrascosa, Antonio Solana-Altabella, Isabel Cano-Ferri, Rafael Colmenares, David Martinez-Cuadron, Stefan Wickenhauser, Juan Miguel Bergua Burgues, Pau Montesinos

Blood (2025) 146 (Supplement 1): 1619.

https://doi.org/10.1182/blood-2025-1619

Published: 2025

Journal Articles

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Bruno Paiva, Leire Burgos, Carmen Gonzalez, Rebeca Rodriguez Veiga, Antonio Solana-Altabella, Pilar Lloret-Madrid, Evelyn Acuña-Cruz, Cristina Gil, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Caballero, Teresa Bernal Del Castillo, Maria Teresa Cedena Romero, Pilar Herrera Puente, Claudia Sossa, Josefina Serrano, Joaquín Sánchez-García, José Luis López Lorenzo, María-Belén Vidriales, Mar Tormo, Monica Romero, Mercedes Colorado, Celina Benavente, Juan Miguel Bergua Burgues, Manuel Pérez-Encinas, Lorenzo Algarra, Carlos Rodríguez-Medina, Dolly Viviana Fiallo Suarez, Raimundo García-Boyero, Luis Felipe Casado Montero, Jorge Labrador, Manuel Barrios García, Beatriz De Rueda Ciller, Marcela Espinoza, Maria Jose Sayas Lloris, Diana Cuervo, María Luz Amigo, Jose-Mario Mariz, Karoll Giovanna Gomez Correcha, Carmen Couto, Esther Perez, Ágata Almela, Susana Vives, Esperanza Lavilla-Rubira, Olga Arce-Fernández, Maria Teresa Olave Rubio, Miguel Lopez, Maria Dolores Madrigal, Lara María Gómez García, Sofia Grille, Sebastián Hidalgo, Daniel García Belmonte, Maria Jose Garcia, Maria Del Carmen Martinez Chamorro, Olga Salamero, Amparo Sempere, Beatriz Martín Herreros, Armando Mena Duran, David Martinez-Cuadron, Pau Montesinos

Blood (2025) 146 (Supplement 1): 5293.

https://doi.org/10.1182/blood-2025-5293

Published: 2025

Journal Articles

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Blood (2025) 146 (Supplement 1): 1694.

https://doi.org/10.1182/blood-2025-1694

Published: 2025

Journal Articles

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

Blood (2025) 146 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2025-1662

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

Blood (2025) 146 (Supplement 1): 40.

https://doi.org/10.1182/blood-2025-40

Published: 2025

Journal Articles

Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial

Blood (2025) 146 (Supplement 1): 5121.

https://doi.org/10.1182/blood-2025-5121

Published: 2025

Journal Articles

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood (2024) 144 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2024-200280

Published: 2024

Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Blood (2024) 144 (Supplement 1): 733.

https://doi.org/10.1182/blood-2024-209097

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Preliminary results from RIVER-81, a phase 2 study of romaciclib (RVU120) + venetoclax in patients with acute myeloid leukemia failing first-line venetoclax + hypomethylating agent (HMA)

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only